vejiga urinaria – Página 2

A Polymorphism in HDM2 (SNP309) Associates with Early Onset in Superficial Tumors, TP53 Mutations, and Poor Outcome in Invasive Bladder Cancer

Sanchez-Carbayo M, Socci ND, Kirchoff T, Erill N, Offit K, Bochner BH and Cordon-Cardo C.

Division of Molecular Pathology, Computational Biology Center, and Departments of Medicine and Urology, Memorial Sloan-Kettering Cancer Center, New York, New York; Centro Nacional de Investigaciones Oncológicas, Madrid, Spain; and BIOPAT, Grup Assistencia, Barcelona, Spain

Abstract

Purpose: The HDM2 gene represents one of the […]

aguardiola 2007-06-01T18:39:00+00:00

Comparison of fluorescence in situ hybridization -FISH- and conventional cytology for early detection of urothelial carcinoma

Nadina Erill¹, Anna Colomer¹, Míriam Gorriz², Naim Hannaoui³, Ruth Román¹, Maria Conangla², Josep M Banús³, Carlos Cordon-Cardo⁴, Xavier Puig ^1,2.

¹BIOPAT, Grup Assistència, Barcelona, Spain; ²HISTOPAT Laboratoris, Barcelona, Spain; ³Institut Català d’Urologia i Nefrologia, ICUN; Barcelona, Spain; and ⁴Division of Molecular Pathology, Memorial Sloan-Kettering Cancer Center, New York, USA.

Bladder tumors have a high recurrence rate, so […]

aguardiola 2004-07-23T17:48:21+00:00

Hibridació in situ Fluorescent -FISH- en la detecció del carcinoma urotelial

N.Erill¹, A.Colomer¹, C Pubill¹, N. Hannaoui³, R. Román¹, M.Conangla², JM. Banús³, C. Cordón¹, X. Puig ^1,2.

¹BIOPAT, Grup Assistència; ²HISTOPAT Laboratoris, ³Institut Català d’Urologia i Nefrologia, ICUN; Barcelona.

El carcinoma urotelial de bufeta és un dels tumors malignes més freqüents al nostre entorn. S’associa a una elevada taxa de recurrència, al voltant d’un 80% dels casos, i […]

aguardiola 2004-06-23T17:46:45+00:00

Genetic and immunophenotype analyses of TP53 in bladder cancer: TP53 alterations are associated with tumor progression

Erill N¹, Colomer A¹, Verdú M², Román R¹, Condom E¹, Hannaoui N³, Banús JM³, Cordón-Cardó C⁴, and Puig X ^1,2.

¹BIOPAT, Grup Assistència, Barcelona; ²HISTOPAT Laboratoris, Barcelona; ³ICUN, Barcelona; and ⁴Division of Molecular Pathology, Memorial Sloan-Kettering Cancer Center, New York.

Altered p53 status is a frequent event in bladder cancer and reported to have prognostic significance. We […]

admin 2004-02-09T22:14:36+00:00

La mutación del P53 en los tumores vesicales. Su valoración mediante IHQ y PCR.

N. Hannaoui, N. Erill*, A. Colomer*, E. Vicente, A. Peña, E. Gómez, M. Verdú*, R. Román*, X. Puig*, JM. Banús

Institut Català d’Urologia i Nefrologia. * BIOPAT. Biopatologia molecular, S.L. Grup Assistència.

Texto completo

Póster presentado en:

LXVIII CONGRESO DE UROLOGÍA

Las Palmas de Gran Canaria, España, 24-28 Mayo 2003

Abstract: Actas Urológicas Españolas 2003;27(4SUPPL 1):182.

aguardiola 2003-05-24T14:25:40+00:00

Previous 1 2